Effects of L-DOPA Monotherapy on Psychomotor Speed and [

Aged Aged, 80 and over Carbidopa / pharmacology Corpus Striatum / drug effects Depressive Disorder, Major / drug therapy Dopamine / metabolism Dopamine Antagonists / pharmacology Drug Combinations Female Humans Levodopa / pharmacology Magnetic Resonance Imaging Male Middle Aged New York Positron-Emission Tomography Raclopride / pharmacology Receptors, Dopamine D2 / metabolism Walking Speed
Gait speed Late-life depression Levodopa Positron emission tomography Processing speed Raclopride

Journal

Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264

Informations de publication

Date de publication:
01 08 2019
Historique:
received: 02 01 2019
revised: 22 03 2019
accepted: 04 04 2019
pubmed: 11 6 2019
medline: 5 8 2020
entrez: 11 6 2019
Statut: ppublish

Résumé

A high-risk subgroup of older patients with depression has slowed processing and gait speeds. This study examined whether carbidopa/levodopa (L-DOPA) monotherapy increased dopamine availability, increased processing/gait speed, and relieved depressive symptoms. Adult outpatients with depression >59 years old underwent baseline [ Thirty-six subjects participated (age, 75.3 ± 7.5 years; 44.4% male). Significant, dose-dependent increases in processing and gait speed were observed with L-DOPA (450-mg dose: processing speed factor score effect size = 0.41, p = .001; dual-task gait speed effect size = 0.43, p = .002). [ By enhancing availability of dopamine, L-DOPA improved processing and gait speed in older adults with depression and significantly decreased [

Sections du résumé

BACKGROUND
A high-risk subgroup of older patients with depression has slowed processing and gait speeds. This study examined whether carbidopa/levodopa (L-DOPA) monotherapy increased dopamine availability, increased processing/gait speed, and relieved depressive symptoms.
METHODS
Adult outpatients with depression >59 years old underwent baseline [
RESULTS
Thirty-six subjects participated (age, 75.3 ± 7.5 years; 44.4% male). Significant, dose-dependent increases in processing and gait speed were observed with L-DOPA (450-mg dose: processing speed factor score effect size = 0.41, p = .001; dual-task gait speed effect size = 0.43, p = .002). [
CONCLUSIONS
By enhancing availability of dopamine, L-DOPA improved processing and gait speed in older adults with depression and significantly decreased [

Identifiants

DOI: 10.1016/j.biopsych.2019.04.007 PMID: 31178096 PMC: PMC6641997
pubmed: 31178096
pii: S0006-3223(19)31272-7
doi: 10.1016/j.biopsych.2019.04.007
pmc: PMC6641997
mid: NIHMS1527169
pii:
doi:

Substances chimiques

Dopamine Antagonists 0
Drug Combinations 0
Receptors, Dopamine D2 0
carbidopa, levodopa drug combination 0
Raclopride 430K3SOZ7G
Levodopa 46627O600J
Carbidopa MNX7R8C5VO
Dopamine VTD58H1Z2X

Banques de données

ClinicalTrials.gov
['NCT02744391']

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Retracted Publication

Langues

eng

Sous-ensembles de citation

IM

Pagination

221-229

Subventions

Organisme : NIMH NIH HHS
ID : R33 MH110029
Pays : United States
Organisme : NIMH NIH HHS
ID : R61 MH110029
Pays : United States

Commentaires et corrections

Type : RetractionIn

Informations de copyright

Copyright © 2019 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Références

Am J Public Health. 1999 Sep;89(9):1346-52
pubmed: 10474551
J Am Geriatr Soc. 2000 Jan;48(1):23-9
pubmed: 10642017
J Gerontol A Biol Sci Med Sci. 2000 Apr;55(4):M221-31
pubmed: 10811152
Neurobiol Aging. 2000 Sep-Oct;21(5):683-8
pubmed: 11016537
Am J Psychiatry. 2000 Dec;157(12):1949-54
pubmed: 11097959
Dement Geriatr Cogn Disord. 2003;15(2):55-66
pubmed: 12566593
Aging Ment Health. 2003 May;7(3):212-6
pubmed: 12775403
J Psychiatr Res. 2003 Mar-Apr;37(2):99-108
pubmed: 12842163
Brain. 2003 Dec;126(Pt 12):2648-55
pubmed: 12937076
J Psychiatr Res. 1963 Dec;1:289-97
pubmed: 14101009
Neuropsychopharmacology. 2004 Jun;29(6):1190-202
pubmed: 15010698
N Engl J Med. 2004 Dec 9;351(24):2498-508
pubmed: 15590952
Am J Geriatr Psychiatry. 2005 Feb;13(2):134-41
pubmed: 15703322
Biol Psychiatry. 2006 Jul 1;60(1):58-65
pubmed: 16414031
J Cereb Blood Flow Metab. 2006 Sep;26(9):1198-212
pubmed: 16421508
Neurosci Biobehav Rev. 2006;30(6):791-807
pubmed: 16901542
J Neurol Neurosurg Psychiatry. 2006 Dec;77(12):1323-8
pubmed: 16952917
Biol Psychiatry. 2006 Dec 15;60(12):1295-8
pubmed: 16996483
Neurology. 2006 Nov 14;67(9):1612-7
pubmed: 17101892
Gait Posture. 2007 Oct;26(4):516-25
pubmed: 17196819
J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
pubmed: 17519979
Neuron. 2007 Jul 19;55(2):325-36
pubmed: 17640532
Arch Gerontol Geriatr. 2008 Jul-Aug;47(1):139-49
pubmed: 17854924
Exp Brain Res. 2008 Mar;185(3):391-8
pubmed: 17973106
Am J Geriatr Psychiatry. 2008 Jan;16(1):65-73
pubmed: 17998306
J Gerontol A Biol Sci Med Sci. 2009 Aug;64(8):896-901
pubmed: 19349593
Psychol Med. 2010 Feb;40(2):225-37
pubmed: 19531277
Neurosci Biobehav Rev. 2010 Apr;34(5):670-7
pubmed: 20026186
J Gerontol A Biol Sci Med Sci. 2010 Aug;65(8):887-95
pubmed: 20418349
Gait Posture. 2012 Jan;35(1):96-100
pubmed: 21940172
Int J Geriatr Psychiatry. 2012 Sep;27(9):893-9
pubmed: 22009869
J Abnorm Psychol. 2012 Aug;121(3):553-8
pubmed: 22775583
J Gerontol A Biol Sci Med Sci. 2013 Apr;68(4):456-64
pubmed: 23051974
Neuroimage. 2013 Feb 1;66:293-300
pubmed: 23142277
Biol Psychiatry. 2013 Apr 1;73(7):639-45
pubmed: 23228328
JAMA Psychiatry. 2013 Aug;70(8):803-11
pubmed: 23760442
J Affect Disord. 2013 Nov;151(2):531-9
pubmed: 23856280
Nat Rev Neurosci. 2013 Sep;14(9):609-25
pubmed: 23942470
Neurosci Biobehav Rev. 2015 Aug;55:247-67
pubmed: 25979140
J Gerontol A Biol Sci Med Sci. 2016 Feb;71(2):221-7
pubmed: 26392405
PLoS One. 2016 Jan 19;11(1):e0147332
pubmed: 26784744
JAMA Psychiatry. 2016 May 1;73(5):525-31
pubmed: 26982217
Lancet Psychiatry. 2016 May;3(5):425-35
pubmed: 26995298
Lancet Psychiatry. 2016 Jul;3(7):628-35
pubmed: 27138970
Am J Psychiatry. 2017 Feb 1;174(2):135-142
pubmed: 27609242
Am J Geriatr Psychiatry. 2016 Nov;24(11):1084-1094
pubmed: 27618646
Front Hum Neurosci. 2017 Aug 03;11:353
pubmed: 28824393
Am J Psychiatry. 2018 Mar 1;175(3):215-224
pubmed: 29202654
Clin Neuropsychol. 2018 Jan-Dec;32(sup1):114-132
pubmed: 29911493
Psychopharmacologia. 1971;20(2):118-27
pubmed: 5104531
Ann Neurol. 1996 May;39(5):561-73
pubmed: 8619540
Arch Gen Psychiatry. 1996 Apr;53(4):305-12
pubmed: 8634008
Psychol Rev. 1996 Jul;103(3):403-28
pubmed: 8759042
Neuroimage. 1996 Dec;4(3 Pt 1):153-8
pubmed: 9345505
Am J Psychiatry. 1998 Mar;155(3):344-9
pubmed: 9501743
J Cogn Neurosci. 1998 Mar;10(2):178-98
pubmed: 9555106
J Gen Intern Med. 1998 Nov;13(11):746-52
pubmed: 9824520
Psychol Med. 1998 Nov;28(6):1311-20
pubmed: 9854272

Auteurs

Bret R Rutherford (BR)

Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York. Electronic address: brr8@cumc.columbia.edu.

Mark Slifstein (M)

Stony Brook University Renaissance College of Medicine, Stony Brook, New York.

Chen Chen (C)

Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York.

Anissa Abi-Dargham (A)

Stony Brook University Renaissance College of Medicine, Stony Brook, New York.

Patrick J Brown (PJ)

Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York.

Melanie W Wall (MW)

Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York.

Nora Vanegas-Arroyave (N)

Columbia University Vagelos College of Physicians and Surgeons, New York, New York.

Yaakov Stern (Y)

Columbia University Vagelos College of Physicians and Surgeons, New York, New York.

Veronika Bailey (V)

New York State Psychiatric Institute, New York, New York.

Emily Valente (E)

New York State Psychiatric Institute, New York, New York.

Steven P Roose (SP)

Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Catéchols › Catécholamines › Carbidopa › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Noyaux gris centraux › Corps strié › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Trouble dépressif › Trouble dépressif majeur › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Catéchols › Catécholamines › Dopamine › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents dopaminergiques › Antagonistes de la dopamine › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Préparations pharmaceutiques › Association médicamenteuse › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés cycliques › Acides aminés aromatiques › Tyrosine › Dopa › Lévodopa › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › États-Unis › Région du Centre-Atlantique › État de New York › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Benzoates › Chloro-benzoates › Raclopride › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs catécholaminergiques › Récepteurs dopaminergiques › Récepteur D2 de la dopamine › Effects of L-DOPA Monotherapy on Psychomotor...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système locomoteur › Mouvement › Locomotion › Démarche › Vitesse de marche › Effects of L-DOPA Monotherapy on Psychomotor...